Deltagen is a leading provider of drug discovery tools and services to the biopharmaceutical industry. Deltagen offers a suite of programs designed to enhance the efficiency of drug discovery including access to biological models as well as both small-molecule and secreted protein drug targets. In addition, Deltagen offers extensive target validation data in the areas of immunology and metabolic diseases. Deltagen’s products and programs have been validated by customers and partners such as Eli Lilly & Co., GlaxoSmithKline, Merck & Co., Millennium Pharmaceuticals and Pfizer.
People
Michael Sember (President/COO)
William Scott (Board Member)
Robert Klein (CTO)
Tom Penn (Board Member)
Daniel Ratto (CFO)
News
Deltagen buys Benten Bio to expand biopharmaceutical business
December 21, 2009 4:36 pm
July 9-10, 2013 San Francisco, CA Tickets On Sale Now Deltagen, a San Mateo, Calif.-based drug distribution company, has acquired… Continue reading ⟩
Biotech chameleons: Quark Pharma aims for $81M IPO
June 6, 2007 5:46 pm
(UPDATED: See below.) For some reason, biotechnology is rife with chameleons — companies that suddenly and radically alter their scientific… Continue reading ⟩